GlucoTrack, Inc.

GCTK

US45824Q6061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:11:33 29/05/2024 am IST			5-day change	1st Jan Change
2.11 ^USD	+3.95%		-10.21%	+61.38%

16/05	Glucotrack?s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study	CI
22/04	GlucoTrack, Inc. announced that it has received $0.5 million in funding	CI

David Podwalski Resigns as an Officer and Director of Integrity Applications, Inc

October 01, 2019 at 02:33 am IST

On October 25, 2019, David Podwalski resigned as an officer and director of Integrity Applications, Inc., retroactive to September 17, 2019, in order to pursue other business interests.

Latest news about GlucoTrack, Inc.

Glucotrack?s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study	16/05	CI
GlucoTrack, Inc. announced that it has received $0.5 million in funding	22/04	CI
Glucotrack Expanding Glucose Monitoring Technology to Epidural Space	16/04	MT
GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring	16/04	CI
Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor	02/04	CI
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors	13/02	CI
GlucoTrack Says Implantable Glucose Monitor Safe With High Level of Accuracy; Shares Rise	02/01	MT
GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor	02/01	CI
GlucoTrack, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
GlucoTrack Finance Chief Jolie Kahn Resigns, James Cardwell Named New CFO	13/23/13	MT
GlucoTrack, Inc. Announces Executive Changes	13/23/13	CI
Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee	31/23/31	CI
GlucoTrack, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor	25/23/25	CI
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2023.	13/23/13	CI
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
GlucoTrack Completes $10 Million Share Sale	17/23/17	MT
Top Midday Decliners	13/23/13	MT
GlucoTrack Prices $10 Million Securities Offering; Shares Slump	13/23/13	MT
Wall Street Set to Open Higher; Jobless Claims Rise as Producer Price Index Comes in Lower Than Expected	13/23/13	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	13/23/13	MT
US Futures Nudge Higher Ahead of Jobless Claims Report	13/23/13	MT
Top Premarket Decliners	13/23/13	MT
GlucoTrack Plans Underwritten Public Offering of Common Shares	13/23/13	MT

GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.

Sector

Biotechnology & Medical Research

Calendar

21/06/2024 - American Diabetes Association Scientific Symposium - Poster No 1010-P

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLUCOTRACK, INC.	+61.38%	1.09Cr
MODERNA, INC.	+54.05%	6.39TCr
IQVIA HOLDINGS INC.	-2.02%	4.18TCr
LONZA GROUP AG	+40.01%	4.05TCr
CELLTRION, INC.	-10.22%	2.72TCr
ICON PUBLIC LIMITED COMPANY	+13.42%	2.65TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	1.87TCr
BIO-TECHNE CORPORATION	+2.89%	1.27TCr
UNITED THERAPEUTICS CORPORATION	+22.40%	1.21TCr
MEDPACE HOLDINGS, INC.	+27.49%	1.21TCr